New Gut-Brain Signaling Drug Targets Prader-Willi Syndrome with Dr. Tien Lee Aardvark Therapeutics TRANSCRIPT
Download PDFJan 8, 2026
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, draws a clear distinction between appetite and hunger and the implications for treating metabolic conditions and managing weight. The Aardvark lead drug candidate, an oral bitter taste receptor agonist designed to activate the gut-brain connection to turn...
Jan 8, 2026
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, draws a clear distinction between appetite and hunger and the implications for treating metabolic conditions and managing weight. The Aardvark lead drug candidate, an oral bitter taste receptor agonist designed to activate the gut-brain connection to turn...
Strategy of the Global Leader in Rare Disease Drugs with Scott Pescatore Recordati TRANSCRIPT
Download PDFDec 11, 2025
Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which...
Dec 11, 2025
Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which...
Advancing Research on Ataxia for Development of Therapeutics and Patient Education with Andrew Rosen NAF TRANSCRIPT
Download PDFNov 13, 2025
Andrew Rosen, Chief Executive Officer of the National Ataxia Foundation, has a dual mission of accelerating research for treatments and cures for Ataxia while supporting the patients affected by this rare disease. Ataxia describes both a group of hereditary genetic diseases and symptoms of lack of coordination seen in...